BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. Its core products include therapies for rare genetic disorders, particularly in the areas of hemophilia and metabolic diseases. Major business segments consist of product development, manufacturing, and sales, with primary revenue sources stemming from its marketed therapies and ongoing clinical trials for new treatments.
The investment profile of BioMarin Pharmaceutical is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion through new product launches. The company shows strong revenue growth and positive earnings surprises, indicating a favorable outlook. This profile may appeal to investors seeking capital appreciation over time.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-03 | Hold | Sell | Weak momentum and high risk overshadow positive fundamentals. |
| 2026-09-17 | Buy | Hold | Strong revenue growth, but mixed momentum signals. |
| 2026-08-20 | — | Buy | Strong revenue growth and positive EPS surprise indicate potential. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-15 | BMO Capital | Target Lowered | 98 → 97 | 64.6 |
| 2026-09-01 | Cantor Fitzgerald | Target Raised | 85 → 86 | 65.31 |
| 2026-09-01 | Piper Sandler | Target Raised | 88 → 90 | 65.23 |
| 2026-08-31 | Jefferies | Target Raised | 104 → 105 | 65.53 |
| 2026-08-31 | Raymond James | Target Raised | 105 → 109 | 65.39 |
| 2026-08-26 | UBS | Update | — → 88 | 66.1008 |
| 2026-08-18 | BMO Capital | Update | — → 98 | 66.99 |
| 2026-08-18 | H.C. Wainwright | Target Lowered | 60 → 59 | 67.7863 |
| 2026-08-17 | Piper Sandler | Target Raised | 82 → 88 | 67.36 |
| 2026-08-17 | Barclays | Target Raised | 105 → 111 | 67.36 |
| 2026-08-10 | Canaccord Genuity | Target Raised | — → 114 | 63.81 |
| 2026-08-07 | Raymond James | Target Raised | 100 → 105 | 63.8 |
| 2026-08-07 | Morgan Stanley | Target Raised | 119 → 124 | 63.84 |
| 2026-08-07 | Stifel Nicolaus | Target Raised | 68 → 70 | 63.55 |
| 2026-08-07 | Oppenheimer | Target Raised | — → 97 | 61.46 |
| 2026-07-07 | RBC Capital | Target Lowered | 66 → 62 | 58.79 |
